Scientific Advisory Board
Prof. Hans Wigzell, M.D., Ph.D.
Professor of Microbiology and Tumor Biology, Karolinska Institutet
Prof. Wigzell is a co-founder of Affibody and has been a member of the Scientific Advisory Board since 2002. He was President of the Karolinska Institute between 1995–2003. He has been Professor in the Department of Immunology at Uppsala University and Department of Immunology at Karolinska Institutet. In 1988, he became Director General of the National Bacteriological Laboratory in Stockholm. In 1990, he was elected Chairman of the EU Concerted Research Programme into AIDS vaccination and from 1990–1992 he was Chairman of the Nobel Committee. In 1993, he was appointed Secretary-General of the Swedish Institute for Infectious Disease Control. Since 1999, he has been a Chief Scientific Advisor to the Swedish Government. Prof. Wigzell was appointed Chairman of the Nobel Assembly in 2000 and in 2002 he was appointed Chairman for the WHO-UNAIDS Vaccine Advisory Committee. He has published more than 600 articles and is a member of the editorial boards of several international journals.
Prof. Mathias Uhlén, Ph.D.
Professor of Microbiology, Royal Institute of Technology
Prof. Uhlén is a co-founder of Affibody and Professor of Microbiology at the Royal Institute of Technology (KTH), Stockholm, Sweden. He was Vice-President of the KTH from 1999-2001. In the early 1980s, Prof. Uhlén cloned and characterized staphylococcal protein A. In the late 1980s, he published research on the use of magnetic microspheres with streptavidin for automated solid phase applications. In the 1990s, his group developed the Affibody® technology. Prof. Uhlén and colleagues also invented a new strategy for DNA analysis called Pyrosequencing. Prof. Uhlén is member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA) and the European Molecular Biology Organization (EMBO). He is Vice-President of the European Proteomics Association (EuPA) and member of the Human Proteome Organization (HUPO) council. He is currently working on the Human Protein Resource Project (HPR), which aims to map the human proteome (www.proteinatlas.org). He is the founder of Pyrosequencing AB (Biotage AB), Affibody AB, SweTreeGenomics AB, Magnetic Biosolutions AB and Creative Peptides AB. Prof. Uhlén has published more than 280 articles focused on the development and use of affinity reagents in biotechnology and biomedicine.